Mesdopetam - Integrative Research Laboratories
Alternative Names: IRL-790Latest Information Update: 28 Mar 2025
At a glance
- Originator Integrative Research Laboratories
- Developer Integrative Research Laboratories; Ipsen
- Class Amines; Antiparkinsonians; Antipsychotics; Fluorobenzenes; Phenyl ethers; Small molecules; Sulfones
- Mechanism of Action Dopamine D3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II/III Parkinson's disease
- No development reported Drug-induced dyskinesia; Psychotic disorders
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for preclinical development in Psychotic-disorders in Sweden
- 12 Mar 2025 Pharmacodynamics data from a preclinical study in levo-dopa induced dyskinesia in Parkinson's disease released by IRLAB
- 27 Feb 2025 Updated efficacy data from a phase IIb/III trial in Parkinson disease released by Integrative Research Laboratories